ZUG, Switzerland--(BUSINESS WIRE)--Galderma:
Continued strong commercial and financial performance in a resilient market
- Galderma delivered continued strong growth across product categories, with net sales up 15% year-on-year on a constant currency basis at 1,914 M USD
- Particularly strong performance of Injectable Aesthetics and Dermo-cosmetics product categories with growth of 32% and 31% on a constant currency basis, respectively
- Volume as a primary growth driver underpins confidence in the resilience and long-term growth fundamentals of the dermatology market
- On track to deliver on 2022 guidance of 12-14% net sales and core EBITDA growth on a constant currency basis
Advancing innovation across its leading dermatology portfolio
- Important clinical milestones achieved, including positive phase III results reinforcing the efficacy and safety of nemolizumab in prurigo nodularis, and positive phase III topline data release of RelabotulinumtoxinA (QM-1114), showing improved glabellar lines (frown) and lateral canthal lines (crow’s feet) with a rapid onset of action and a long duration
- Significant launches across all product categories, including Alluzience®, the first ready-to-use liquid form of botulinum toxin type A in Europe; Twyneo®, the first ever tretinoin and benzoyl peroxide combination to treat facial acne; and Epsolay®, the first and only microencapsulated benzoyl peroxide topical treatment of bumps and blemishes of rosacea
|
“We are very pleased with how the company has performed in the first half of 2022 and we remain on track to deliver on our full-year guidance. Our performance demonstrates strong growth momentum despite challenging global conditions. We continue to advance innovation and science across our portfolio, with important clinical milestones reached for nemolizumab and RelabotulinumtoxinA, and significant new product launches. In a dermatology market that has proven resilient in the first half of the year, we believe Galderma is well positioned to meet consumer demand through its premiumization strategy and broad channel exposure.”
FLEMMING ØRNSKOV, M.D., MPH CHIEF EXECUTIVE OFFICER |
